tiprankstipranks
Trending News
More News >
Elekta AB (EKTAY)
OTHER OTC:EKTAY
Advertisement

Elekta AB (EKTAY) Price & Analysis

Compare
24 Followers

EKTAY Stock Chart & Stats


Elekta AB News

EKTAY FAQ

What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.43 and its highest was $7.14 in the past 12 months.
    What is Elekta AB’s market cap?
    Elekta AB’s market cap is $1.90B.
      When is Elekta AB’s upcoming earnings report date?
      Elekta AB’s upcoming earnings report date is Nov 26, 2025 which is in 58 days.
        How were Elekta AB’s earnings last quarter?
        Elekta AB released its earnings results on Aug 28, 2025. The company reported $0.029 earnings per share for the quarter, beating the consensus estimate of N/A by $0.029.
          Is Elekta AB overvalued?
          According to Wall Street analysts Elekta AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Elekta AB pay dividends?
            Elekta AB pays a Semiannually dividend of $0.126 which represents an annual dividend yield of 0.26%. See more information on Elekta AB dividends here
              What is Elekta AB’s EPS estimate?
              Elekta AB’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Elekta AB have?
              Elekta AB has 368,588,000 shares outstanding.
                What happened to Elekta AB’s price movement after its last earnings report?
                Elekta AB reported an EPS of $0.029 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.77%.
                  Which hedge fund is a major shareholder of Elekta AB?
                  Currently, no hedge funds are holding shares in EKTAY

                  Elekta AB Stock Smart Score

                  Company Description

                  Elekta AB

                  Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

                  Elekta AB (EKTAY) Earnings & Revenues

                  EKTAY Company Deck

                  EKTAY Earnings Call

                  Q1 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call presented a mixed picture. While there were strong performances in the EMEA region and successful new product launches, challenges in the U.S. and China markets, as well as declining margins, were notable concerns. The improvement in cash flow and FDA clearance for the Leksell Gamma Knife were positive, but the overall financial performance showed signs of strain.View all EKTAY earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AptarGroup
                  Baxter International
                  Becton Dickinson
                  Hologic
                  Masimo

                  Ownership Overview

                  0.02%<0.01%99.97%
                  Insiders
                  <0.01% Other Institutional Investors
                  99.97% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis